Article date: February 2019
By: Grégoire Narjoux, Justine Clarenne, Brahim Azzouz, Pauline‐Saraï Zeller, Florian Slimano, Olivier Bouché in Volume 85, Issue 2, pages 454-456
Polypharmacy of elderly oncology patients and fragmented medication management are well‐known risk factors for drug–drug interactions (DDIs). These interactions can occur among antineoplastic, ongoing chronic treatment(s) and chemotherapy‐associated treatments, like antiemetics. Clinically relevant interactions based on enzyme‐ or transporter‐inhibition phenomena of active drugs can increase the frequency of their DDIs. We describe a strongly suspected elderly cancer patient's DDI between aprepitant and opium powder in the context of an irinotecan‐based regimen manifested by nightmares and visual hallucinations. We discuss this DDI's hypothetical pharmacological mechanisms and management.
DOI: 10.1111/bcp.13810
View this article